Eric Loumeau Sells 2,983 Shares of AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) insider Eric Loumeau sold 2,983 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $43.26, for a total transaction of $129,044.58. Following the completion of the transaction, the insider directly owned 13,251 shares in the company, valued at $573,238.26. The trade was a 18.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

AnaptysBio Stock Up 3.0%

Shares of NASDAQ:ANAB opened at $45.21 on Thursday. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $52.47. The business has a 50 day moving average of $42.31 and a 200-day moving average of $31.22. The stock has a market cap of $1.25 billion, a PE ratio of -16.03 and a beta of 0.32.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. Equities research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a share buyback program on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to buy up to 9.6% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Strong quarter: AnaptysBio reported an EPS beat and materially higher revenue versus consensus in its most recent quarter — a result that underpins the stock rerating and analyst optimism. Read More.
• Positive Sentiment: Share repurchase: The board authorized up to $100 million in buybacks (~9.6% of shares), which reduces float and signals management confidence — typically supportive for the stock. Read More.
• Positive Sentiment: Analyst support: Multiple firms maintain Buy/Overweight ratings and the consensus target remains above the current price, helping attract demand from institutional and retail investors. Read More.
• Neutral Sentiment: Event catalyst: CEO Daniel Faga will present at the J.P. Morgan Healthcare Conference on Jan. 13 — a common venue for new data, partnership or strategy updates, but movement depends on what is announced. Read More.
• Neutral Sentiment: Institutional flows: Several funds have increased or initiated positions recently, which can provide steady demand but also raises the possibility of larger block trades if they rebalance. Read More.
• Negative Sentiment: Insider selling: Multiple insiders, including CEO Daniel Faga (15,309 shares), CFO Dennis Mulroy and others, filed Form 4s disclosing sales at about $43.26 on Jan. 5 — a move that can be read negatively by the market even if for diversification or tax reasons. Read More.

Analyst Ratings Changes

ANAB has been the topic of several research analyst reports. Wall Street Zen raised AnaptysBio from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Truist Financial lifted their price target on AnaptysBio from $20.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. Barclays reduced their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Finally, Wedbush restated an “outperform” rating and issued a $50.00 price objective on shares of AnaptysBio in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $60.40.

Hedge Funds Weigh In On AnaptysBio

A number of large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. increased its holdings in AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock worth $25,719,000 after purchasing an additional 822,975 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of AnaptysBio by 63.1% in the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock worth $14,705,000 after acquiring an additional 305,950 shares during the period. 683 Capital Management LLC grew its position in AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after buying an additional 304,373 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its position in AnaptysBio by 2.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock valued at $11,588,000 after purchasing an additional 10,005 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of AnaptysBio by 145.6% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock worth $11,343,000 after acquiring an additional 219,648 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.